Search
Liposomal prostaglandin E1
go.drugbank.com/drugs/DB05391InvestigationalThe liposomal formulation of PGE-1 changes the drug’s dynamics and improve its therapeutic index in ways that PGE-1 alone could not achieve. … Liposome-encapsulated form of prostaglandin E1 (Liprostin) is known to be a potent vasodilator and platelet inhibitor as well as an anti-inflammatory and anti-thrombotic agent.
Brofaromine
go.drugbank.com/drugs/DB13876ExperimentalCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome2,5-Dimethoxy-4-ethylthioamphetamine
go.drugbank.com/drugs/DB13940Experimental2,5-Dimethoxy-4-ethylthioamphetamine (ALEPH-2) is a phenylisopropylamine derivative with alleged anxiolytic and hallucinogenic properties.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Receptor AgonistsGnRH pharmaccine
go.drugbank.com/drugs/DB05815ExperimentalThe pharmaccine is administered intramuscularly to the patient by injection and induces an immune response or production of antibodies in the patient, which neutralize GnRH thus removing it from circulation … The GnRH pharmaccine consists of synthetic peptides (constructed to "look like" GnRH), which are bound chemically to a carrier and suspended in a proprietary "delivery vehicle".
Midecamycin
go.drugbank.com/drugs/DB13456InvestigationalIn this molecule, an acetoxy group is substituted on the position 9 of the 16-member ring and on position 4 of the terminal sugar. … Midecamycin is a naturally occurring 16-membered macrolide [A33072] that fits under the category of acetoxy-substituted macrolide antibiotics.
MF101
go.drugbank.com/drugs/DB05052InvestigationalMF101 is a novel estrogen receptor beta (ERβ) selective agonist and unlike currently available hormone therapies, does not activate the estrogen receptor alpha (ERα), known to be implicated in tumor formation … MF101 is an oral drug designed for the treatment of hot flashes and night sweats in peri-menopausal and menopausal women.
Camostat
go.drugbank.com/drugs/DB13729Investigational[A193842,A193848] It was first described in the literature in 1981, as part of research on the inhibition of skin tumors in mice. … [A198807] Camostat mesylate inhibits cholecystokinin, pro-inflammatory cytokines, and serine proteases, leading to it being investigated for multiple indications including the treatment of COVID-19.
Otilonium
go.drugbank.com/drugs/DB13500InvestigationalMixtures: BROMURO DE OTILONIO + SIMETICONA 40MG + 200MGPRTX-100
go.drugbank.com/drugs/DB05947InvestigationalThese binding interactions enable the compound to modulate the function of these cells and restore the balance of the immune system. … PRTX-100 is a highly-purified form of Staphylococcal Protein A that binds directly to monocytes and a subset of B-cells that are involved in the development and progression of various autoimmune diseases
CYT007-TNFQb
go.drugbank.com/drugs/DB05758ExperimentalThe vaccine should allow for administration of low amounts of drug to individual patients (in the microgram range) and for convenient dosing schedules. … CYT007-TNFQb is an active immunization therapy that aims at providing a novel treatment to people suffering from RA or psoriasis.